NASDAQ:ITMN - InterMune Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Receive ITMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ITMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ITMN
CUSIP45884X10
WebN/A
Phone+1-415-4662200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

InterMune (NASDAQ:ITMN) Frequently Asked Questions

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Has InterMune been receiving favorable news coverage?

Media stories about ITMN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. InterMune earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.

What other stocks do shareholders of InterMune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InterMune investors own include Agios Pharmaceuticals (AGIO), Booking (BKNG), Alphabet (GOOG), Intercept Pharmaceuticals (ICPT), Align Technology (ALGN), Celgene (CELG), Gilead Sciences (GILD), Illumina (ILMN), Medivation (MDVN) and Netflix (NFLX).

How do I buy shares of InterMune?

Shares of ITMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact InterMune?

InterMune's mailing address is 3280 Bayshore Blvd, BRISBANE, CA 94005-1021, United States. The biotechnology company can be reached via phone at +1-415-4662200.


MarketBeat Community Rating for InterMune (NASDAQ ITMN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe ITMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel